28 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Alzheimer's Drug Discovery Foundation Young Investigator Scholarships for the 14th International Conference on Alzheimer's Drug Discovery
Ten ADDF Young Investigator Scholarships will be presented. Each of these 10 scholarships provides:
A single registration to attend the conference
Opportunity to present a poster at the conference
Name recognition in the program and on the conference website
Scholarship recipients are expected to attend the 14th International Conference on Alzheimer's Drug Discovery to receive the award.
The applicant must be a graduate student or a postdoctoral fellow. Postdoctoral applicants should have no more than four years of postdoctoral training including postdoctoral training at other institutions. Physician-scientists are eligible to apply. The program has no geographic restrictions. Women and minorities are strongly encouraged to apply.
All applications must be submitted by July 19, 2013. Winners will be announced via email.
The following materials must be submitted for consideration by the ADDF’s Young Investigator Scholarship Review Committee:
Application Form (sumbitted online)
Current curriculum vitae that includes a list of publications (by email to email@example.com)
Request for Proposals: Tourette Syndrome Association Grant and Fellowship Program
The Tourette Syndrome Association requests research grant proposals from Ph.D. and M.D. researchers in basic and clinical studies on all aspects of Tourette syndrome.
All applications relevant to Tourette Syndrome will be considered.
Areas of particular interest for this cycle are:
• Neuropathology (utilizing tissue in the TSA Brain Tissue Collection)
• Experimental Therapeutics
• Animal Models
Candidates must have a M.D., Ph.D., or equivalent. Previous experience in the field of movement disorders is desirable, but not essential. Applicants may reside outside the United States.
Post-Doctoral Fellowships: up to $40,000 for 1 year
Research Grant Awards: up to $75,000 for 1 year or up to $150,000 for two years
TSA will consider reasonable requests for:
• Salaries (for US institutions, NIH salary caps apply)
• Laboratory supplies and other research-related expenses
• Travel expenses for investigators (up to $1,500 per year)
• Research equipment up to $5,000 (excluding equipment for personal or office use [e.g. computers])
• Indirect costs of up to 10% may be included, but the total value of the grant may not exceed the levels stated above
For preliminary screening, a Pre-Proposal is required.
Due Date: September 6, 2013
Submit the filled-in Pre-proposal form as an email attachment to: firstname.lastname@example.org
Full Grant Proposal
Due Date: November 15, 2013
Detailed instructions will be sent to applicants who are invited to apply for a research grant.
Awards Announced: March, 2014
718-224-2999, ext. 222 or email
Request for Proposals: Creative Computational Approaches to Accelerate Drug Discovery for the Treatment and Prevention of Dementia
Current methods of drug discovery have had limited success at predicting clinical efficacy of investigational therapies in patients with Alzheimer’s disease and other age-related dementias.
Computational modeling, systems biology and pharmacology, and translational bioinformatics represent
a tremendous yet relatively under-developed opportunity to accelerate and improve this process particularly for dementias.
The Alzheimer’s Drug Discovery Foundation (ADDF) program on Aging & Alzheimer’s Disease Prevention is requesting proposals for innovative computational approaches to map disease and predict the efficacy of drugs to treat and prevent dementia. A variety of approaches and outcomes will be considered.
Priority will be given to interdisciplinary teams composed of computational and biology/disease experts, and to proposals that use and perhaps develop open-access databases of biological and clinical data.
The winning submission(s) will present the most scientifically compelling, novel, and viable program to accelerate drug discovery.
Funding Opportunity #1.
Novel computational approaches to modeling drug efficacy on a key therapeutic target for Alzheimer’s disease.
Quantitative systems pharmacology and other network modeling approaches are of interest, as well as translational bioinformatics approaches to rational drug repurposing and rational combinatorial therapies.
Priority will be given to targets other than beta-amyloid and acetylcholinesterase, including but not limited to neuroinflammation, mitochondrial function, insulin sensitivity, cholesterol and ApoE, and the neurovascular
Some applications may benefit from the use of the databases including but not limited to:
- The Gene Expression Omnibus (GEO) open-access database of genomics data and ProfileChaser, a related web server
-Life Sciences databases.
Funding Opportunity #2.
Novel computational approaches to model disease risk and progression based on risk factors. Research increasingly indicates that Alzheimer’s is a multi-factorial disease that can develop along different trajectories with multiple risk factors such as genotype, comorbidities, dietary and environmental factors.
Some applications may benefit from the use of open-access databases of epidemiological data
including but not limited to:
- The National Alzheimer’s Coordinating Center (NACC) (http://www.alz.washington.edu),
-The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (http://adni.loni.ucla.edu/data-samples/access
- The C-Path online Data Repository (CODR) for Alzheimer’s Disease (http://www.c-path.org/CAMDcodr.cfm).
Mechanism(s) of support:
Up to $150,000 in funding is available for each grant for one-year duration, with the possibility of follow-
on funding for computational or experimental research.
The deadline date for applications is September 5, 2013.
Submission of a Letter of Intent (LOI) is required prior to August 22, 2013.
Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee. The award winner (s) will be publicly announced in Spring 2014.
All letters of intent and applications must be submitted electronically at www.alzdiscovery.org. Detailed application instructions are available on the website.
Request for Proposals: Accelerating Drug Discovery for Frontotemporal Dementias
Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia (FTD) and related disorders is advancing, creating new potential targets for drug discovery. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).
Priority areas for this program include:
• Development of biomarkers to accelerate drug development and early diagnosis
• Innovative pilot clinical trials
• Target validation studies
• Development and testing of novel high throughput screening assays
• Medicinal chemistry on lead compounds
• Identification and in vitro testing of potentially disease modifying lead compounds
• ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds
• Testing of lead compounds in a relevant animal model for preclinical proof of concept
Please note: this funding will not support applications for basic research.
Mechanism (s) of support:
ADDF/AFTD will provide grants for one-year duration (up to $150,000 each) with the possibility of follow-on funding.
Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program
Submission of a Letter of Intent (LOI) is required prior to August 22nd, 2013.
Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including
members of AFTD’s Medical Advisory Council.
Applications from biotechnology companies will also be reviewed by ADDF’s external Business Advisory Board.
Award winners will be publicly announced in Spring 2014.
All letters of intent and applications must be submitted electronically at www.alzdiscovery.org.
Young Investigator Award Presidential Grants from the NMS-Group
Symposium Summary: Sleep research in neurodegeneration has become a rapidly growing field of research with major clinical and scientific impact. REM sleep behavior disorder (RBD) as a hallmark and risk factor of neurodegeneration has gained prominent recognition in the last 15 years, identifying those patients at increased risk for neurodegenerative diseases. Idiopathic RBD patients will most likely comprise the ideal population for enrollment in neuroprotective trials in the future. We learn from sleep disorders about the pathophysiology of brain functioning in Parkinson syndromes and we can better define various phenotypes of Parkinson disease. Animal studies will be another focus in this research area, to study the interaction of Gaba-ergic, cholinergic and dopaminergic neurotransmission in the generation of REM sleep, REM without atonia and RBD.
Application Process: We invite all young researchers who are active in the field of clinical or experimental sleep research in a topic related to neurodegeneration (i.e. Parkinson syndromes or Alzheimer disease) or neurobiology of REM sleep to submit their abstracts and apply for a travel grant – with the chance of being selected to present their work in a special symposium entitled “Neurodegeneration and Sleep” at the 5th World Congress on Sleep Medicine in Valencia, Spain.
STEP ONE – Submit your abstract online at www.wasmcongress.com/abstract/submit_form.php.
-Select the box “Young Investigator”
STEP TWO – Email WASM at email@example.com. Within your email add why you are applying for this award with a short letter (max 200 words) and biosketch.
Deadline: June 30, 2013
Requirement: 35 years old or younger OR less than 3 years in that topic.
If selected your 10 minute oral presentation will be included in a special symposium during the meeting on Tuesday, October 1st from noon to 1:30 PM.
A travel grant of $1000-1500 (depending on distance of travel) will be provided to symposium speakers.
Request for Proposals: Funding Opportunities for Kennedy’s Disease Research
The Kennedy’s Disease Association (KDA) is planning to fund one or more research grants this fall to further the understanding of the pathological mechanisms of Kennedy’s Disease.
The KDA projects that funding for each grant will be up to $25,000.
Applications from junior investigators and from senior post-doctoral fellows are encouraged.
Your proposals must be received by Friday, June 21, 2013.
Rosalinde Gilbert Innovations in Alzheimer’s Disease Caregiving Legacy Awards
With continuing support from The Rosalinde and Arthur Gilbert Foundation, Family Caregiver Alliance (FCA) is pleased to oversee the annual Rosalinde Gilbert Innovations in Alzheimer's Disease Caregiving Legacy Awards program in its sixth year.
Three awards of $20,000 each will be awarded to nonprofit organizations, government agencies or universities responding to a community need with a program or project which focuses primarily on family/informal caregivers of adults with Alzheimer's disease and related dementias. Only agencies operating within the continental United States are eligible to apply. One award will be granted in each of these categories:
Creative Expression: This award will go to programs or projects that use imaginative and creative approaches in supporting persons with dementia or family/informal caregivers of persons with Alzheimer's disease and related dementias. Some examples are programs or projects using art, music, theatre, journaling, multimedia (e.g. film, documentary, radio) or other types of creative expression.
Diverse/Multicultural Communities: This award will go to programs or projects that provide services, support or other types of outreach to family/informal caregivers of persons with Alzheimer's disease or related dementias in diverse ethnic, age diversity, religion/spirituality, gender, rural, low income, and LGBT or other communities.
Policy and Advocacy: This award will go to programs or projects that advocate for systems change for the benefit of family/informal caregivers or care recipients with Alzheimer's disease or related dementias. These efforts could focus on legislation, executive or administrative changes, advocacy campaigns, or any other action to strengthen the public or private sector's recognition and support of family/informal caregivers.
Applications are available, online only. The closing deadline for 2013 applications is 5 p.m. (Pacific Time), Friday, August 16, 2013. Award announcements will be made by late November 2013. Award recipients will be honored at the 2014 Annual Conference of the American Society on Aging (ASA). Participates will be invited to present information about their awarded program or project at the conference. Travel stipends will be available for the conference.
Eligibility and Submission Conditions
Nonprofit organizations, government agencies and universities responding to a community need with a program or project that focuses primarily on family/ informal caregivers of adults with Alzheimer's disease and related dementias are eligible to apply. Family or informal caregivers are unpaid caregivers. The term includes family members, friends, domestic partners and neighbors. Support for family/informal caregivers need not be the primary mission of the organization, agency or university.
Nonprofit applicants must submit proof of their 501(c) (3) status or other nonprofit status by attaching a copy of their nonprofit designation letter to their application. For-profit entities are not eligible to apply.
The nominated program or project has to have been active during the calendar year of 2012 and/or 2013. If the program or project involves a major culminating event, that event must have occurred prior to application deadline.
For the Policy & Advocacy and Creative Expression categories, program or project may be related to either family/informal caregivers or persons with dementia or both.
For the Diversity/Multicultural Communities category, program/project must be specific to family/informal caregivers of persons with Alzheimer's disease or related dementias.
The applicant or other designated program or project representatives must be willing to share information about their program with others, including a presentation at a national professional conference, and to write up additional information to appear on FCA's website and/or future publications. Award recipients may also be asked to provide information about how the award was used to further advance the mission of the organization, agency, or university.
Application must be received by the extended deadline of 5 p.m. (Pacific Time), on Friday, August 16, 2013.
Applicants must apply electronically using the designated online system.
Applicants must designate the category in which they would like to be considered. Applicants are competing only against others within their chosen category. If the judges feel that the applicant would be better suited for another category, they will contact the applicant directly.
ALS Therapy Alliance Grants Program
Thank you for your interest in submitting a proposal for grant funding to the ALS Therapy Alliance (ATA). Our organization traditionally awards grants from one to three years in term ranging from $100,000 to $1 million in funding to both non- and for-profit companies. National and international companies are eligible to apply.
The following outline will help you prepare the information needed for our next funding review, which happens twice a year in April and November.
Please note grant submission deadlines and number of copies requested in order to ensure timely processing of your application. The ALS Therapy Alliance does not cover indirect costs.
If you have questions about the submission process or this application, please contact Ray Bisson, Grants Manager at (603) 664-5005 or firstname.lastname@example.org, or visit our FAQ page.
What to include with your grant proposal
ATA grant applications should follow the following format and adhere strictly to the maximum page limits (using only 11 point font or greater):
■ Abstract (1 page)
■ Background and Significance (2 pages)
■ Preliminary Data (2 pages)
■ Experimental Plan (3 pages)
■ References (no limit)
■ Budget Justification
■ NIH Biosketch (including present and pending support, 4 pages maximum) for PI's, post-docs and others involved in the project (excluding laboratory technicians)
■ Letters of collaboration and support
Grant proposal submission deadlines
To have your grant proposal reviewed at our April meeting, please submit by March 15th. To have your grant proposal reviewed at our November meeting, please submit by October 15th.
Where to send your grant proposal
Please email your proposal in PDF format to email@example.com.
Request for Application: A-T Children's Project
Request for Application (RFA) for March 1, 2013 and September 1, 2013
Seed funding is now available for innovative proposals that seek to identify and validate biomarkers of A-T disease progression and that can be used to monitor therapeutic efficacy in clinical trials.
Please note that investigator-initiated proposals are also welcome for the March 1 and September 1 grant submission deadlines; however priority will be given to proposals that address the above referenced RFA.
We welcome investigators to contact Cynthia Rothblum-Oviatt, PhD, our Science Coordinator, if help is needed forming collaborations and/or obtaining reagents for A-T/ATM research.
Cynthia Rothblum-Oviatt, PhD
A-T Children's Project
5300 W. Hillsboro Blvd., Suite 105
Coconut Creek, FL 33073